Interpretation of Amino-Terminal Pro-Brain Natriuretic Peptide Levels in the HPS and the CORONA Study

Journal of the American College of Cardiology

Volumn 52, Issue 13, 2008, Pages 1104-1105

  Cleland, John G F ^a   Squire, Iain ^a   Ng, Leong ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ROSUVASTATIN;

AMINO TERMINAL SEQUENCE; CLINICAL TRIAL; HEART FAILURE; HUMAN; LETTER; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MULTICENTER STUDIES AS TOPIC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 51449085613     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.04.070     Document Type: Letter

References (3)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 360 (2002) 7-22
2. Heart Protection Study Collaborative Group. N-terminal pro-B-type natriuretic peptide, vascular disease risk and cholesterol reduction among 20,536 patients in the MRC/BHF Heart Protection Study. J Am Coll Cardiol 49 (2007) 311-319
3. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261